King buys Jones in $3.2bn stock transaction
King Pharmaceuticals is acquiring Jones Pharma in an all-stock pooling-of-interests transaction that values Jones at $3.2bn. Each common share of Jones will be exchanged for 1.125 shares of King common, a premium of (pr)16% based on their 10-day pre-announcement market averages.
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com